Elan sells Myobloc rights

ISEQ-listed Elan Corporation today announced that it has completed the sale of its worldwide rights to Myobloc/Neurobloc injectable solution to Solstice Neurosciences a newly-formed company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products.

Included in the sale are the related intellectual property, the product inventory, and the manufacturing facility.